Abstract
Background: Checkpoint inhibitors, anti-programmed cell death 1 (PD-1) and cytotoxic T lymphocyte- associated antigen 4 (CTLA-4) have been shown to be effective in the treatment of various malignancies. Though rare, the novelty of immunotherapy necessitates further investigations of its potentially serious and even morbid consequent toxicities. To better understand the clinical evidence of hematologic toxicities, we conducted a retrospective data collection study to help clinicians identify the risks burdening patients undergoing immunotherapy.
Methods: A total of 490 patient charts from the Saskatchewan Cancer Agency will be reviewed. Charts reviewed will be pertaining to patients that received immunotherapy for any indication from 2013, when immunotherapy began being administered within the system, to May 30th, 2020. Data will be collected from charts including patients that received anti-P1/PDL1 and/or anti-CTLA4, and experienced anemia, neutropenia or thrombocytopenia within a time frame of therapy. Pertinent information is then input to a data collection tool using REDCap.
Results: N/A (Will be available once we complete the study by the summer of 2023)
Conclusion: The goal of this study is to identify the proportion and context of patients treated at the Allan Blair Cancer Centre experiencing immunotherapy related toxicities. The outcome of this research may assist clinicians in identifying the risks burdening patients undergoing cancer treatment and identify best management practices to reduce patient morbidity and mortality.
Disclosures
No relevant conflicts of interest to declare.
Author notes
Asterisk with author names denotes non-ASH members.
